skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Sorafenib in metastatic MTC – a case report and minireview of the literature

Case report

(2006) Views  (636) Full article downloads

Authors: Mila Petrova, Zhasmina Mihaylova, Albena Fakirova

Published Date May 2010 Volume 2010:3 Pages 55 - 58
DOI: http://dx.doi.org/10.2147/IMCRJ.S9384

Mila Petrova1, Zhasmina Mihaylova1, Albena Fakirova2

1Hematology and Oncology Department, 2Pathology Department, Medical Military Academy, Sofia, Bulgaria

Abstract: Medullary thyroid cancer (MTC) is a rare and only surgically treatable disease with early development of metastases and bad prognosis. Due to the lack of efficient systemic treatment, new strategies and approaches are needed to better the patients’ outcome. One of the most promising treatment options is the use of tyrosine multikinase inhibitors, which appear to have some effect on the disease progression with tolerable toxicity. Most of them affect many key pathways in the cancer genesis and have proven their effect in different malignancies. We report a case of a young patient with metastatic MTC treated successfully for two months with sorafenib.

Keywords: medullary thyroid cancer, tumor response, cardiotoxicity, TKIs






 

Other articles by Dr Milla Petrova



Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Fulminate anaerobic bacteremia after chemotherapy for metastatic breast cancer despite the prophylactic use of GCSF
Temporomandibular joint dislocation due to acute propranolol intoxication
Congestive heart failure in subjects with thyrotoxicosis in a black community
Acute pyogenic discitis in a degenerative intervertebral disc in an adult
Early pre-eclampsia unmasks underlying IgA nephropathy
Effectiveness of a combination of cyclosporine A, suplatast tosilate and prednisolone on periodic oscillating hypereosinophilia
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer
Role of vandetanib in the management of medullary thyroid cancer